Regenerative Tissue Engineering and Transplantation

再生组织工程与移植

基本信息

  • 批准号:
    8256913
  • 负责人:
  • 金额:
    $ 1.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-01-01 至 2012-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This proposal requests support for a Keystone Symposia meeting entitled Regenerative Tissue Engineering and Transplantation, organized by Rocky S. Tuan, Farshid Guilak and Anthony Atala, which will be held in Breckenridge, Colorado from April 1 - 6, 2012. Tissue engineering and regenerative medicine is a dynamic, translational research field that amalgamates life sciences, engineering, and clinical medicine for the purpose of restoring structure and function to diseased, damaged or injured tissues and organs. Current efforts focus on the application of stem and progenitor cells, bioactive factors and biomaterial scaffolds in transplantation procedures to affect regenerative therapies. Breakthroughs in bladder and tracheal reconstruction and highly promising approaches for solid organ regeneration as well as musculoskeletal and nerve repair have been achieved. Effective cell sourcing, optimal assembly and fabrication of tissue-derived and synthetic biomaterial scaffolds, and targeted regulation of therapeutic and immunomodulatory functions of stem cells represent some of the current challenges in this field. In this Keystone Symposia meeting on Regenerative Tissue Engineering and Transplantation, exciting technological and intellectual advances in the field will be synthesized by expert scientists, engineers, and clinicians to assess and expand the landscape in regenerative engineering and transplantation. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Mechanisms of Whole Organ Regeneration, which will share an opening and closing keynote address as well as two plenary sessions with this meeting. More specifically, the pairing of these 2 meetings represents a highly unusual opportunity for crosstalk between the more applications-driven field of tissue engineering and regenerative medicine, and the very basic research being explored in the field of whole organ regeneration. PUBLIC HEALTH RELEVANCE: Structural and functional loss of tissues and organs through disease, injury, and trauma is a significant challenge in medicine. Development of advanced regenerative and transplantation technologies is of essential benefit to these affected individuals. The Keystone Symposia meeting on Regenerative Tissue Engineering and Transplantation will directly address challenges in this field. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Mechanisms of Whole Organ Regeneration, which will share an opening and closing keynote address as well as two plenary sessions with this meeting.
描述(由申请人提供):本提案请求支持由Rocky S.图安、法希德·吉拉克和安东尼·阿塔拉,将于2012年4月1日至6日在科罗拉多州布雷肯里奇举行。组织工程和再生医学是一个动态的,转化的研究领域,融合了生命科学,工程学和临床医学,旨在恢复患病,受损或受伤组织和器官的结构和功能。目前的努力集中在干细胞和祖细胞,生物活性因子和生物材料支架在移植过程中的应用,以影响再生治疗。膀胱和气管重建的突破性进展以及实体器官再生以及肌肉骨骼和神经修复的非常有前途的方法已经实现。有效的细胞来源,组织衍生和合成生物材料支架的最佳组装和制造,以及干细胞的治疗和免疫调节功能的靶向调节代表了该领域当前的一些挑战。在这次关于再生组织工程和移植的Keystone研讨会上,该领域令人兴奋的技术和知识进步将由专家科学家,工程师和临床医生合成,以评估和扩大再生工程和移植的前景。同时举行的关于全器官再生机制的会议将大大加强跨学科互动的机会,该会议将与本次会议分享开幕式和闭幕式主旨演讲以及两次全体会议。更具体地说,这两个会议的配对代表了一个非常不寻常的机会,可以在组织工程和再生医学的应用驱动领域与整个器官再生领域正在探索的非常基础的研究之间进行交流。 公共卫生相关性:由于疾病、损伤和创伤导致的组织和器官的结构和功能丧失是医学中的重大挑战。先进的再生和移植技术的发展对这些受影响的人至关重要。再生组织工程和移植的Keystone研讨会会议将直接解决这一领域的挑战。同时举行的关于全器官再生机制的会议将大大加强跨学科互动的机会,该会议将与本次会议分享开幕式和闭幕式主旨演讲以及两次全体会议。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James Wavell Aiken其他文献

James Wavell Aiken的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James Wavell Aiken', 18)}}的其他基金

Malaria
疟疾
  • 批准号:
    8396987
  • 财政年份:
    2013
  • 资助金额:
    $ 1.56万
  • 项目类别:
Type 2 Immunity: Initiation, Maintenance, Homeostasis and Pathology
2 型免疫:启动、维持、稳态和病理
  • 批准号:
    8399493
  • 财政年份:
    2013
  • 资助金额:
    $ 1.56万
  • 项目类别:
Noncoding RNAs in Development and Cancer
非编码 RNA 在发育和癌症中的作用
  • 批准号:
    8391064
  • 财政年份:
    2013
  • 资助金额:
    $ 1.56万
  • 项目类别:
Emerging Topics in Immune System Plasticity: Cellular Networks, Metabolic Control
免疫系统可塑性的新兴主题:细胞网络、代谢控制
  • 批准号:
    8400276
  • 财政年份:
    2013
  • 资助金额:
    $ 1.56万
  • 项目类别:
Multiple Sclerosis
多发性硬化症
  • 批准号:
    8391042
  • 财政年份:
    2013
  • 资助金额:
    $ 1.56万
  • 项目类别:
The Life of a Stem Cell: From Birth to Death
干细胞的生命:从出生到死亡
  • 批准号:
    8252536
  • 财政年份:
    2012
  • 资助金额:
    $ 1.56万
  • 项目类别:
Frontiers in HIV Pathogenesis, Therapy and Eradication
HIV发病机制、治疗和根除的前沿
  • 批准号:
    8260640
  • 财政年份:
    2012
  • 资助金额:
    $ 1.56万
  • 项目类别:
The Biology of Cytokines
细胞因子的生物学
  • 批准号:
    8199540
  • 财政年份:
    2012
  • 资助金额:
    $ 1.56万
  • 项目类别:
Drug Resistance and Persistence in Tuberculosis
结核病的耐药性和持久性
  • 批准号:
    8255025
  • 财政年份:
    2012
  • 资助金额:
    $ 1.56万
  • 项目类别:
NF-kappaB Signaling and Biology: From Bench to Bedside
NF-kappaB 信号传导和生物学:从实验室到临床
  • 批准号:
    8253117
  • 财政年份:
    2012
  • 资助金额:
    $ 1.56万
  • 项目类别:

相似海外基金

ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    $ 1.56万
  • 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
  • 批准号:
    10932514
  • 财政年份:
    2023
  • 资助金额:
    $ 1.56万
  • 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    $ 1.56万
  • 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
  • 批准号:
    10709085
  • 财政年份:
    2023
  • 资助金额:
    $ 1.56万
  • 项目类别:
Advanced Development of Gemini-DHAP
Gemini-DHAP的高级开发
  • 批准号:
    10760050
  • 财政年份:
    2023
  • 资助金额:
    $ 1.56万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    $ 1.56万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10710595
  • 财政年份:
    2022
  • 资助金额:
    $ 1.56万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    $ 1.56万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
  • 批准号:
    10710588
  • 财政年份:
    2022
  • 资助金额:
    $ 1.56万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10788051
  • 财政年份:
    2022
  • 资助金额:
    $ 1.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了